{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:58:09Z","timestamp":1790114289506,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1124\/jpet.118.253708","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T01:06:52Z","timestamp":1546996012000},"page":"446-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases"],"prefix":"10.1016","volume":"368","author":[{"given":"Gautham","family":"Gampa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroz S.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Mladek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.118.253708_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.112.048322","article-title":"Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma","volume":"41","author":"Agarwal","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.253708_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1124\/jpet.118.253708_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-015-0293-5","article-title":"Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma","volume":"14","author":"Atefi","year":"2015","journal-title":"Mol Cancer"},{"key":"10.1124\/jpet.118.253708_bib5","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.118.253708_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471141755.ph1416s52","article-title":"Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery","volume":"52","author":"Carlson","year":"2011","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1124\/jpet.118.253708_bib7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","article-title":"Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.118.253708_bib9","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1021\/mp500435s","article-title":"Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib","volume":"11","author":"Choo","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.118.253708_bib10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.253708_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1124\/jpet.118.253708_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.31052","article-title":"The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors","volume":"142","author":"de Gooijer","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1124\/jpet.118.253708_bib13","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.253708_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.118.253708_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib17","doi-asserted-by":"crossref","unstructured":"Elenbaas B, Singh L, Boccia A, Cullen P, Peng H, Rohde E, Raimundo B, Kumaravel G, and Joseph I (2010) Poster presentation: BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics; 2010 November 16\u201319","DOI":"10.1016\/S1359-6349(10)71810-3"},{"key":"10.1124\/jpet.118.253708_bib18","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib20","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1124\/dmd.107.015222","article-title":"In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids","volume":"35","author":"Frid\u00e9n","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.253708_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40495-016-0072-z","article-title":"Challenges in the delivery of therapies to melanoma brain metastases","volume":"2","author":"Gampa","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/jpet.118.253708_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2017.06.008","article-title":"Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities?","volume":"123","author":"Gampa","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.118.253708_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.118.253708_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.1997.371","article-title":"Cerebral metastases of cutaneous melanoma","volume":"76","author":"Gupta","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.118.253708_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.118.253708_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1124\/jpet.118.253708_bib28","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1021\/acs.jmedchem.5b00067","article-title":"Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells","volume":"58","author":"Henry","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.118.253708_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/humu.20481","article-title":"Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants","volume":"28","author":"Hocker","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1124\/jpet.118.253708_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1124\/jpet.118.253708_bib31","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.118.253708_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.118.253708_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11095-018-2455-9","article-title":"Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine","volume":"35","author":"Kim","year":"2018","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.118.253708_bib34","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib35","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.253708_bib36","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.118.253708_bib39","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.253708_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.118.253708_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10543409808835241","article-title":"An extension of Satterthwaite\u2019s approximation applied to pharmacokinetics","volume":"8","author":"Nedelman","year":"1998","journal-title":"J Biopharm Stat"},{"key":"10.1124\/jpet.118.253708_bib42","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-16-1327","article-title":"Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases","volume":"22","author":"Osswald","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.118.253708_bib43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.118.253708_bib44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1124\/jpet.118.253708_bib45","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/jco.2013.31.15_suppl.2547","article-title":"MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: phase I study","volume":"31","author":"Rasco","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.118.253708_bib46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.118.253708_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.118.253708_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.03.003","article-title":"Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: a systematic review","volume":"45","author":"Spagnolo","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/jpet.118.253708_bib49","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.118.253708_bib50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.118.253708_bib51","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","article-title":"Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases","volume":"42","author":"Vaidhyanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.118.253708_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","article-title":"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1124\/jpet.118.253708_bib53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.phrs.2017.11.006","article-title":"P-glycoprotein (MDR1\/ABCB1) and Breast Cancer Resistance Protein (BCRP\/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice","volume":"129","author":"Wang","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.118.253708_bib54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.118.253708_bib55","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-15-0136-T","article-title":"Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors","volume":"14","author":"Whittaker","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524261164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524261164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.118.253708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:56:20Z","timestamp":1739994980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524261164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0022356524261164"],"URL":"https:\/\/doi.org\/10.1124\/jpet.118.253708","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.118.253708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}